Emergency care in oncology: potential complications of treatment with immune checkpoint inhibitors


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Immune checkpoint inhibitors aimed to blocking the cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand PD-L1, show a high potential for antitumor activity in many oncological diseases including melanoma, nonsmall cell lung cancer, renal cell carcinoma, and urothelial carcinoma. Some of these drugs are already becoming the main line of therapy for the late stages of melanoma and other malignant neoplasms. Immune checkpoint inhibitors, however, have a particular profile of side effects, causing immune-mediated adverse events (IMAEs). These side effects can occur in any organ system, but the most common are lesions of the skin, gastrointestinal tract, endocrine and respiratory systems. IMAEs are usually treated with glucocorticosteroids which suppress the excessive activity of the immune response. Doctors of any specialties should know this class of drugs and their AE profile in order to recognize patients with IMAEs in time and prescribe the necessary therapy. This article provides a short description of the main immune checkpoints inhibitors and discusses the most common AEs that doctors may encounter in their practice.

全文:

受限制的访问

作者简介

R. Nuriev

Sechenov First Moscow State Medical University; Clinical Center Vitamed

Moscow, Russia

M. Sekacheva

Sechenov First Moscow State Medical University

Moscow, Russia

A. Bondarenko

Clinical Center Vitamed

Moscow, Russia

M. Baranova

Clinical Center Vitamed; Russian Medical Academy of Continuous Professional Education

Department of Oncology Moscow, Russia

S. Sletina

Clinical Center Vitamed

Moscow, Russia

E. Poddubskaya

Sechenov First Moscow State Medical University; Clinical Center Vitamed

Email: podd-elena@yandex.ru
PhD, Deputy Director of the Clinical Center of Sechenov University for Oncology 8, Trubetskaya Street, Moscow 119991, Russian Federation

参考

  1. Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64. doi: 10.1038/nrc3239.
  2. Postow M., Callahan M., Wolchok J. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33(17):1974-82. Doi: 10.1200/ JCO.2014.59.4358.
  3. Нуриев РИ, Караулов А.В., Киселевский М.В. Новые стратегии лечения пациентов с онкологическими заболеваниями: иммунотерапевтический подход. Иммунология. 2017;38(1):39-48. doi: 10.18821/0206-4952-2017-38-1-39- 48.
  4. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271-75. Doi: 10.1126/ science.1160062.
  5. Tumeh PC, Harview C.L., Yearley J.H., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568. doi: 10.1038/nature13954.
  6. Larkin J., Chiarion-Sileni V, Gonzalez R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34. Doi: 10.1056/ NEJMoa1504030.
  7. Horn L, Spigel D.R., Vokes E.E., et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924-33. Doi: 10.1200/ JCO.2017.74.3062.
  8. Robert C, Schachter J., Long G.V, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-32. doi: 10.1056/NEJMoa1503093
  9. Rosenberg J.E., Hoffman-Censits J., Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4.
  10. Hodi F.S., O'day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. doi: 10.1056/NEJMoa1003466.
  11. Sharma P, Allison J.P Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205-14. doi: 10.1016/j.trecan.2015.07.008.
  12. Zamarin D., Postow M.A. Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther. 2015;150:23-32. doi: 10.1016/j.pharmthera.2015.01.003.
  13. Patel S.A., Minn A.J. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48(3):417-33. doi: 10.1016/j.immuni.2018.03.007.
  14. Wolchok J.D., Chiarion-Sileni V., Gonzalez R., et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345-56. Doi: 10.1056/ NEJMoa1709684.
  15. Marin-Acevedo J.A., Dholaria B., Soyano A.E., et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39. doi: 10.1186/s13045-018-0582-8.
  16. Sharma ft, Allison J.P The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi: 10.1126/science.aaa8172.
  17. Champiat S., Lambotte O., Barreau E., et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2015;27(4):559- 74. Doi: 10.1093/ annonc/mdv623.
  18. Weber J.S., Hodi F.S., Wolchok J.D., et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785-92. Doi: 10.1200/ JCO.2015.66.1389.
  19. Postow M.A. Managing immune checkpointblocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;35(76):76-83. Doi: 10.14694/ EdBook_AM.2015.35.76.
  20. Friedman C.F., Proverbs-Singh T.A., Postow M.A. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA. Oncol. 2016;2:1346-53. Doi: 10.1001/ jamaoncol.2016.1051.
  21. Spain L., Diem S., Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60. doi: 10.1016/j.ctrv.2016.02.001.
  22. Brahmer J., Reckamp K.L., Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-35. Doi: 10.1056/ NEJMoa1504627.
  23. Borghaei H., Paz-Ares L., Horn L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-39. Doi: 10.1056/ NEJMoa1507643.
  24. Culakova E., Thota R., Poniewierski M.S., et al. Patterns of chemotherapy associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med. 2014;3(2):434-44. doi: 10.1002/cam4.200.
  25. Проценко С.А., Антимоник Н.Ю., Берштейн Л.М. и др. Практические рекомендации по коррекции иммуноопосредованных нежелательных явлений. Злокачественные опухоли: Практические рекомендации RUSSCO 2017. Т. 7 (№ 3s2):592-620.
  26. Postow M.A., Sidlow R., Hellmann M.D. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-68. doi: 10.1056/NEJMra1703481.
  27. Downey S.G, Klapper J.A., Smith F.O., et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22):6681-88. doi: 10.1158/1078-0432.CCR-07-0187.
  28. Grob J., Hamid O., Wolchok J., et al. 9312 antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs). Ejc Suppl. 2009;2(7):580. doi: 10.1016/S1359-6349(09)71956-1.
  29. Harmankaya K., Erasim C., Koelblinger C., et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. 2011;28(4):1140-44. Doi: 10.1007/ s12032-010-9606-0.
  30. Horvat T.Z., Adel N.G., Dang T.O., et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clinl Oncol. 2015;33(28):3193. doi: 10.1200/JC0.2015.60.8448.
  31. Naidoo J., Page D.B., Li B.T., et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375-91. doi: 10.1093/annonc/mdv383.
  32. Eigentler T.K., Hassel J.C., Berking C., et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7-18. doi: 10.1016/j.ctrv.2016.02.003.
  33. Weber J.S., Kahler K.C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21 ):2691 -9 7. Doi: 10.1200/ JCO.2012.41.6750.
  34. Michot J.M., Bigenwald C., Champiat S., et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48. Doi: 10.1016/j. ejca.2015.11.016.
  35. Brahmer J.R., Lacchetti C., Schneider B.J., et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-68. doi: 10.1200/JCO.2017.77.6385.
  36. Pag s C., Gornet J.M., Monsel G., et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23(3):227-30. doi: 10.1097/CMR.0b013e32835fb524.
  37. Merrill S.P, Reynolds P, Kalra A., et al. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother. 2014;48(6):806-10. doi: 10.1177/1060028014528152.
  38. Bernardo S.G., Moskalenko M., Pan M., et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res. 2013;23(1):47-54. Doi: 10.1097/ CMR.0b013e32835c7e68.
  39. Hammers H., Plimack E.R., Infante J.R., et al. 1050O Phase I Study Of Nivolumab In Combination With Ipilimumab In Metastatic Renal Cell Carcinoma (MRCC). Ann Oncol. 2014;25(Suppl. 4):iv361-2.
  40. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-44. doi: 10.1056/NEJMoa1305133.
  41. Kim K.W., Ramaiya N.H., Krajewski K.M., et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Inv N Drugs. 2013;31(4):1071-77. doi: 10.1007/s10637-013-9939-6.
  42. Ribas A., Hodi F.S., Callahan M., et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365-66. doi: 10.1056/NEJMc1302338.
  43. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. doi: 10.1056/NEJMoa1200690.
  44. Delaunay M., Cadranel J., Lusque A., et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2):1700050. doi: 10.1183/13993003.00050-2017.
  45. Nishino M., Giobbie-Hurder A., Hatabu H., et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA. Oncol. 2016;2(12):1607-16. Doi: 10.1001/ jamaoncol.2016.2453.
  46. Rashdan S., Minna J.D., Gerber D.E. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet. Respir Med. 2018;6(6):472-78. doi: 10.1016/S2213-2600(18)30172-3.
  47. Suresh K., Voong K.R., Shankar B., et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol. 2018;13(12):1930-39. doi: 10.1016/j.jtho.2018.08.2035.
  48. Naidoo J., Wang X., Woo K.M., et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709. Doi: 10.1200/ JCO.2016.68.2005.
  49. Kottschade L., Brys A., Peikert T., et al. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res. 2016;26(5):469-80. doi: 10.1097/CMR.0000000000000273.
  50. Yu C., Chopra I.J., Ha E. A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis. Endocrinol Diab Metab Case Reports. 2015;2015. doi: 10.1530/EDM-14- 0092.
  51. Martin-Liberal J., Furness A.J., Joshi K., et al. Antiprogrammed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother. 2015;64(6):765-67. Doi: 10.1007/ s00262-015-1689-1.
  52. Ryder M., Callahan M., Postow M.A., et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer. 2014;21(2):371-81. doi: 10.1530/ERC-13-0499.
  53. Corsello S.M., Barnabei A., Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361-75. doi: 10.1210/jc.2012-4075.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2019
##common.cookie##